ACC.18 | Video: ODYSSEY Outcomes

Drs. Peter Block and Philippe G. Steg discuss cardiovascular outcomes with PCSK9-inhibitor, alirocumab, after acute coronary syndrome.

Clinical Topics: Acute Coronary Syndromes, Dyslipidemia, Stable Ischemic Heart Disease, Lipid Metabolism, Nonstatins, Novel Agents, Statins, Chronic Angina

Keywords: ACC18, ACC Annual Scientific Session, Angina, Stable, Cholesterol, LDL, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Acute Coronary Syndrome, Maximum Tolerated Dose, Brain Ischemia, Stroke, Antibodies, Monoclonal, Angina, Unstable, Apolipoproteins B, Myocardial Infarction, Coronary Disease, Treatment Outcome, Hospitalization, Subtilisins


< Back to Listings